Enzymatica Balance Sheet Health

Financial Health criteria checks 6/6

Enzymatica has a total shareholder equity of SEK189.5M and total debt of SEK2.5M, which brings its debt-to-equity ratio to 1.3%. Its total assets and total liabilities are SEK211.9M and SEK22.5M respectively.

Key information

1.3%

Debt to equity ratio

SEK 2.52m

Debt

Interest coverage ration/a
CashSEK 96.90m
EquitySEK 189.49m
Total liabilitiesSEK 22.45m
Total assetsSEK 211.95m

Recent financial health updates

Recent updates

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Jul 20
Is Enzymatica (STO:ENZY) Using Too Much Debt?

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Jul 22
Is Enzymatica (STO:ENZY) Using Too Much Debt?

Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Feb 18
Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Estimating The Fair Value Of Enzymatica AB (STO:ENZY)

Jan 12
Estimating The Fair Value Of Enzymatica AB (STO:ENZY)

Things Look Grim For Enzymatica AB (STO:ENZY) After Today's Downgrade

Jul 20
Things Look Grim For Enzymatica AB (STO:ENZY) After Today's Downgrade

Financial Position Analysis

Short Term Liabilities: ENZY's short term assets (SEK128.5M) exceed its short term liabilities (SEK21.1M).

Long Term Liabilities: ENZY's short term assets (SEK128.5M) exceed its long term liabilities (SEK1.3M).


Debt to Equity History and Analysis

Debt Level: ENZY has more cash than its total debt.

Reducing Debt: ENZY's debt to equity ratio has reduced from 4.1% to 1.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ENZY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ENZY has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 12% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 04:08
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Enzymatica AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jakob LembkeABG Sundal Collier Sponsored
Peter SelleiPenser Access
Maria Karlsson OsipovaPenser Access